Infliximab in the treatment of plaque psoriasis

Therapy

Volumn 4, Issue 4, 2007, Pages 399-406

  Saraceno, Rosita ^a   Gottlieb, Alice B ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Early treatment; Infliximab; Plaque psoriasis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EMOLLIENT AGENT; ETANERCEPT; ETRETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; NEUTRALIZING ANTIBODY; PLACEBO; PROTEIN P55; PROTEIN P75; PSORALEN; RETINOID; SALICYLIC ACID; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BINDING AFFINITY; BONE MARROW DEPRESSION; CHILL; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DIVERTICULITIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FLUSHING; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG INFECTION; LUPUS LIKE SYNDROME; LUPUS VULGARIS; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; PATHOGENESIS; PHOTOTHERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; PYELONEPHRITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; TUBERCULOSIS;

EID: 34447554447     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.4.399     Document Type: Article

References (30)

1. Lowes MA, Bowcock AM, Krueger JG: Pathogenesis and therapy of psoriasis. Nature 22, 866-873 (2007).
2. Lebwohl M: Psoriasis. Lancet 361, 1197-1204 (2003).
3. Scher RK: Psoriasis of the nail. Dermatol. Clin. 3, 387-394 (1985).
4. Green L, Meyers OL, Gordon W, Briggs B: Arthritis in psoriasis. Ann. Rheum. Dis. 40, 366-369 (1981).
5. Wang H, Peters T, Kess D et al.: Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J. Clin. Invest. 116(8), 2105-2014 (2006).
6. Gottlieb SL, Gilleaudeau P, Johnson R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med 1, 442-447 (1995).
7. Bowcock AM, Krueger JG: Getting under the skin: the immunogenetics of psoriasis. Nat. Rev. Immunol. 5, 699-711 (2005).
8. Gottlieb AB, Chamian F, Masud S et al.: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 15, 2721-2729 (2005).
9. Krueger G, Koo J, Lebwohi M, Menter A. Stern RS, Rolstad T: The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch. Dermatol. 137, 280-284 (2001).
10. Brown KK, Rehmus WE, Kimball AB: Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J. Am. Acad. Dermatol. 55, 607-613 (2006).
11. Dubertret L, Mrowietz U, Ranki A et al.: European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br. J. Dermatol. 155, 729-736 (2006).
12. Gottlieb AB: Infliximab in psoriasis. J. Am. Acad. Dermatol. 49, S112-S117 (2003).
13. Gottlieb AB, Masud S, Ramamurthi R et al.: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48, 68-75 (2003).
14. Krueger JG: The immununologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46, 1-23 (2002).
15. Gottlieb AB, Chang CK, Posnett DN et al. Detection of transforming growth factor a in normal, malignant, and hyperproliferative human keratinocytes. J. Exp. Med. 167, 670-675 (1988).
16. Knight DM, Trinh H, Le J et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30, 1443-1453 (1993).
17. Chaudhari U, Romano P, Mulcahy LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357, 1842-1847 (2001).
18. Gottlieb AB, Chaudad U, Mulcahy LD et al. Infliximab monotherapy provides rapid and substantial benefit for plaque-type psoriasis. J. Am. Acad. Dermatol. 48, 829-835 (2003).
19. Reich K, Nestle FO, Papp, K et al.: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet 366, 1367-1374 (2005).
20. Kalb RE, Gurske J: Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J. Am. Acad. Dermatol. 53, 616-622 (2005).
21. Smith CH, Jackson K, Bashir SJ: Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br. J. Dermatol. 155, 160-169 (2006).
22. Ahmad K, Rogers S: Three years' experience with infliximab in recalcitrant psoriasis. Clin. Exp. Dermatol. 31, 630-633 (2006).
23. Schopf RE, Aust H, Knop J: Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab. J. Am. Acad. Dermatol. 46, 886-891 (2002).
24. Gottlieb AB, Evans R, Li S et al.: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controled trial. J. Am. Acad. Dermatol. 51, 534-542 (2004).
25. Oh CJ, Das KM, Gottlieb AB: Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol. 42, 829-830 (2000).
26. Menter A, Feldman SR, Weinstein GD et al.: A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 56, 1-15 (2007).
27. Antoni CE, Kavanaugh A, Kirkham B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52, 1227-1236 (2005).
28. Kavanaugh A, Krueger GG, Beutler A et al.: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through one year of treatment: results from the IMPACT 2 trial. Ann. Rheum. Dis. 66, 498-505 (2007).
29. Gladman DD, Brockbank J: Psoriatic arthritis. Expert. Opin. Investig. Drugs 9. 1511-1522 (2000).
30. Saraceno R, Griffiths CE: A European perspective on the challenges of managing psoriasis. J. Am. Acad. Dermatol. 54, S81-S84 (2006).